Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ABCL Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 21, 2026
Report Source: 2026 1st Quarter Report
Abcellera Biologics Inc. Stock Analysis ABCL
United States Health Care Small Cap Report: AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Read More Abcellera Biologics Inc (ABCL) Chart
Key Statistics of Abcellera Biologics Inc (ABCL)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.48Volume
5.52MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.57BAvg. Volume
6.47MDividend Yield
-Financial Metrics & Statements of Abcellera Biologics Inc (ABCL)
FAQ's for Abcellera Biologics Inc (ABCL)
- According to Musaffa’s Shariah screening methodology, Abcellera Biologics Inc (ABCL) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Abcellera Biologics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Abcellera Biologics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Abcellera Biologics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Abcellera Biologics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Abcellera Biologics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.